Table 3.
Predefined criteria
Criteria | Standards for scientific evidence | |
1 | Effect | Effect estimated in meta-analyses of placebo-controlled trials should be correctly conveyed [12–14]. |
2 | Relapse of depression | Withdrawal symptoms may be mistaken for relapse [15,16]; no good evidence for advising long-term treatment [17–19]; depression usually remits spontaneously [20]. |
3 | Chemical imbalance | No evidence for a chemical imbalance as a cause of depression, or for drugs fixing or correcting an imbalance of chemicals in the brain [19,21–23]. |
4 | Functioning/Quality of life | No evidence that drugs help people return to work, reduce sick leave and improve their social relationships [19]. |
5 | Sexual function | The drugs cause sexual dysfunction in many people, e.g. lack of libido and impotence [24]. |
6 | Emotional numbing | The drugs may blunt people’s emotions [25]. |
7 | Suicidality | The drugs may increase the risk of suicidality, with no age limit [19,26–29]. |
8 | Addiction | Objectively and subjectively, the drugs are addictive [30–32]. |
9 | Withdrawal effects | The drugs may cause withdrawal effects, which may make it difficult for the patients to come off them [15,16,19,32]. |
10 | Foetal harms | The drugs may cause neonatal abstinence syndrome [33]; it is less clear whether they may cause foetal malformations [34,35]. |
11 | Duration of treatment | Randomised trials have only tested the drugs in the short term [19]. There is no evidence for their benefit in the long term [17,18]. |
12 | Tapering | People must not stop the drugs suddenly [15]; a tapering is needed, often for a duration of many months [16,32,36]. |
13 | Psychotherapy | Psychotherapy is effective [37,38] and may reduce the risk of suicide [39]. |
14 | Off-label prescribing | The drugs are generally not approved for young people [40]. |